SCHEMBL782824

SCHEMBL782824

COCc1nc2c([nH]1)c(=O)n(C)c(=O)n2CC(C)C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
PDE5A O76074 12/20 1.00
PDE1A P54750 5/20 1.00
PDE1B Q01064 5/20 1.00
PDE1C Q14123 5/20 1.00
MEN1 O00255 1/20 1.00
CYP1A2 P05177 1/20 1.00
CYP3A4 P08684 1/20 1.00
TSHR P16473 1/20 1.00
CYP2C19 P33261 1/20 1.00
BLM P54132 1/20 1.00
KMT2A Q03164 1/20 1.00
PDE2A O00408 4/20 0.66
PDE3B Q13370 4/20 0.57
PDE3A Q14432 4/20 0.57
ADORA1 P30542 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7402437 0.99 PDE5A (0.97) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL1111560 0.90 PDE5A (0.81) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL2917588 0.85 PDE5A (0.74) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL4622439 0.84 PDE5A (0.73) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL7089133 0.82 PDE5A (0.70) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL10960178 0.82 PDE5A (0.70) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL14889319 0.82 PDE5A (1.00) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL4622802 0.81 PDE5A (0.68) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL897036 0.80 PDE1A (1.00) PDE5APDE1APDE1BPDE1CMEN1
SCHEMBL9927457 0.80 PDE1A (0.66) PDE5APDE1APDE1BPDE1CMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 268 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-222882781-U M.2 signal integrity test fixture supporting PCIE5.0 深圳市同泰怡信息技术有限公司 2025-05-16 CN claimed
CN-118819027-A Front-end readout electronics system of scintillator detector based on multichannel waveform digitizing chip 中国科学院紫金山天文台 2024-10-22 CN claimed
CN-117743053-A High-speed signal processing method, device, equipment and system 西安易朴通讯技术有限公司 2024-03-22 CN claimed
US-20220378782-A1 KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2022-12-01 US claimed
US-20190083455-A1 METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-03-21 US claimed
US-20170105964-A1 METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-04-20 US claimed
US-20160045617-A1 TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY LEE JUSTIN C (US) 2016-02-18 US claimed
WO-2015195894-A1 METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS THE GENERAL HOSPITAL CORPORATION (US) 2015-12-23 WO claimed
WO-2014169087-A2 TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-10-16 WO claimed
US-20080193385-A1 COMPOSITIONS AND METHODS FOR TREATING NEUROPATHY MAIBACH TODD 2008-08-14 US claimed
US-20050009847-A1 Compounds and methods for increasing neurogenesis NEURONOVA AB (COMPANY REGISTRATION NO. 556703-0118) (SE) 2005-01-13 US claimed
US-6812239-B2 DETERMINING IF COMPOUND INHIBITS PHOSPHODIESTERASE 1C (PDE1C) IN PANCREATIC ISLET BETA-CELLS ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY 2004-11-02 US claimed
WO-2004045592-A2 COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS NEURONOVA AB (SE) 2004-06-03 WO claimed
US-6586478-B2 Administering nitrogen oxide mimetic CELLEGY CANADA (CA) 2003-07-01 US claimed
EP-1305328-A2 MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES Lyles, Mark B. (US) 2003-05-02 EP claimed
US-20020103350-A1 Materials and methods for binding nucleic acids to surfaces LYLES MARK B (US) 2002-08-01 US claimed
WO-2002008237-A2 MATERIALS AND METHODS FOR BINDING NUCLEIC ACIDS TO SURFACES LYLES MARK B (US) 2002-01-31 WO claimed
EP-0502043-B1 UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR LVMH RECH (FR) 1995-03-01 EP claimed
EP-0502043-A1 UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR. LVMH RECH (FR) 1992-09-09 EP claimed
WO-1991007945-A1 UTILIZATION OF XANTHINES, OPTIONALLY INCORPORATED IN LIPOSOMES IN ORDER TO HELP THE PIGMENTATION OF SKIN OR HAIR LVMH RECHERCHE (FR) 1991-06-13 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220378782-A1 KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF MECP2, SLC1A2, GRIN2C PDE5A 3425/4885PDE1A 1674/4885PDE1B 1494/4885
US-20160045617-A1 TREATMENT OF PROXIMAL SPINAL MUSCULAR ATROPHY CELF2, SMN1; SMN2, GRM8 PDE5A 248/4885PDE1A 55/4885PDE1B 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.